home > ict > spring 2020 > role of comparators in clinical trial designs
International Clinical Trials

Role of Comparators in Clinical Trial Designs

Case studies provide real insight in how to choose comparators for rare diseases and oncology studies. Drug development is a very complex, long, and expensive process. Once a suitable molecule is identified, then clinical trials are undertaken to establish the effect of an intervention.

Treatment effects are efficiently isolated by controlling for bias, and confounding and minimising variation. Key features of clinical trials that are used to meet this objective are randomisation (possibly with stratification), adherence to intent-to-treat principles, blinding, prospective evaluation, and use of a control group. Compared to other types of study designs (e.g., casecontrol studies, cohort studies, and case reports), randomised trials have high validity, but are more difficult and expensive to conduct.

The gold standard of any scientific evidence is data generated from a randomised control trial. In these studies, a pool of patients is randomly assigned to two groups that receive different treatment. An experimental group will receive the investigational medicinal product (IMP) and a control group can receive a range of different interventions. The most commonly utilised are a placebo (an inert compound that has no effect on the endpoints measured) and an active comparator (usually the standard of care [SOC]) for the indication being tested for. The choice of medication for the control group depends on the nature of the disease. For example, oncology patients are always put on medication for ethical reasons.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Dr Vanessa Dekou, Managing Director, Clinical Services International (CSI) has extensive experience in drug development from preclinical to registration and commercialisation strategies and has secured product registration for several orphans and first-in-class drugs. She has successfully designed and executed numerous trials all over the world. As such, Vanessa understands all the challenges and requirements of supplying comparators to clinical trials and ensuring trials are delivered on time and on budget. Vanessa has worked with some of the largest biopharmaceutical and biotechnology companies to provide innovative solutions. At CSI, Vanessa is responsible for providing bespoke solutions to their clients to ensure comparator sourcing is not a rate-limiting step in the successful delivery of trials. She also works closely with pharma manufacturers to safeguard the supply chain and remain on the front line of advances in drug development. Vanessa has a PhD in Cardiovascular Genetics from University College of London, UK, an MBA from Cambridge, UK and a Masters in Market Access from University of Lyon, France.
Print this page
Send to a friend
Privacy statement
News and Press Releases

PRA Enhances COVID-19 Monitoring Program with Integration of Microsoft Healthcare Bot Service

PRA Health Sciences, Inc. announced today the enhancement of its commercial Health Harmony COVID-19 Monitoring Program with the integration of the Microsoft Healthcare Bot service.
More info >>

White Papers

Interface: Drug Delivery Devices


A family is packing for its annual summer trek to the cottage by the lake. Along with fishing gear, sunscreen, and life vests, the checklist also includes another kind of life saver an autoinjector that delivers two doses of epinephrine to treat anaphylaxis, a severe and potentially lifethreatening allergic reaction.
More info >>

Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement